Unknown

Dataset Information

0

Time to Clinically Relevant Fracture Risk Scores in Postmenopausal Women.


ABSTRACT: BACKGROUND:Clinical practice guidelines recommend use of fracture risk scores for screening and pharmacologic treatment decisions. The timing of occurrence of treatment-level (according to 2014 National Osteoporosis Foundation guidelines) or screening-level (according to 2011 US Preventive Services Task Force guidelines) fracture risk scores has not been estimated in postmenopausal women. METHODS:We conducted a retrospective competing risk analysis of new occurrence of treatment-level and screening-level fracture risk scores in postmenopausal women aged 50 years and older, prior to receipt of pharmacologic treatment and prior to first hip or clinical vertebral fracture. RESULTS:In 54,280 postmenopausal women aged 50 to 64 years without a bone mineral density test, the time for 10% to develop a treatment-level FRAX score could not be estimated accurately because of rare incidence of treatment-level scores. In 6096 women who had FRAX scores calculated with bone mineral density, the estimated unadjusted time to treatment-level FRAX ranged from 7.6 years (95% confidence interval [CI], 6.6-8.7) for those aged 65 to 69, to 5.1 years (95% CI, 3.5-7.5) for those aged 75 to 79 at baseline. Of 17,967 women aged 50 to 64 with a screening-level FRAX at baseline, 100 (0.6%) experienced a hip or clinical vertebral fracture by age 65 years. CONCLUSIONS:Postmenopausal women with sub-threshold fracture risk scores at baseline were unlikely to develop a treatment-level FRAX score between ages 50 and 64 years. After age 65, the increased incidence of treatment-level fracture risk scores, osteoporosis, and major osteoporotic fracture supports more frequent consideration of FRAX and bone mineral density testing.

SUBMITTER: Gourlay ML 

PROVIDER: S-EPMC5474146 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Clinical practice guidelines recommend use of fracture risk scores for screening and pharmacologic treatment decisions. The timing of occurrence of treatment-level (according to 2014 National Osteoporosis Foundation guidelines) or screening-level (according to 2011 US Preventive Services Task Force guidelines) fracture risk scores has not been estimated in postmenopausal women.<h4>Methods</h4>We conducted a retrospective competing risk analysis of new occurrence of treatment-l  ...[more]

Similar Datasets

| S-EPMC4411185 | biostudies-literature
| S-EPMC6070433 | biostudies-literature
| S-EPMC7560920 | biostudies-literature
| S-EPMC5470770 | biostudies-literature
| S-EPMC2682463 | biostudies-literature
| S-EPMC6822158 | biostudies-literature
| S-EPMC2277453 | biostudies-other
| S-EPMC10905300 | biostudies-literature
| S-EPMC4832288 | biostudies-literature
| S-EPMC7385675 | biostudies-literature